Uren

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for uro-oncology and specialty urological conditions. The company's core technology, RTGel, is a proprietary sustained-release, hydrogel-based platform designed to improve the therapeutic profile of existing drugs by increasing their dwell time in the urinary tract. Their lead commercial product, Jelmyto, is the first FDA-approved non-surgical treatment for low-grade upper tract urothelial cancer. UroGen is also advancing a robust pipeline, including UGN-102 for low-grade non-muscle invasive bladder cancer and various immuno-oncology candidates.